Oric Pharmaceuticals Stock Revenue
| ORIC Stock | USD 7.91 0.12 1.54% |
Oric Pharmaceuticals fundamentals help investors to digest information that contributes to Oric Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Oric Stock. The fundamental analysis module provides a way to measure Oric Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oric Pharmaceuticals stock.
| Last Reported | Projected for Next Year |
Oric | Revenue |
Oric Pharmaceuticals Company Revenue Analysis
Oric Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Oric
Projected quarterly revenue analysis of Oric Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Oric Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Oric Pharmaceuticals' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Oric Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Oric Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Oric Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oric Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oric Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oric Pharmaceuticals by comparing valuation metrics of similar companies.Oric Pharmaceuticals is currently under evaluation in revenue category among its peers.
Oric Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oric Pharmaceuticals from analyzing Oric Pharmaceuticals' financial statements. These drivers represent accounts that assess Oric Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oric Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 681.4M | 664.3M | 169.4M | 460.2M | 506.5M | 577.8M |
Oric Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oric Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oric Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Oric Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Oric Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oric Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oric Pharmaceuticals' value.| Shares | State Street Corp | 2024-12-31 | 1.8 M | Boxer Capital Management, Llc | 2024-12-31 | 1.7 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Superstring Capital Management Lp | 2024-12-31 | 1.6 M | Nea Management Company, Llc | 2024-12-31 | 1.6 M | Balyasny Asset Management Llc | 2024-12-31 | 1.6 M | First Turn Management Llc | 2024-12-31 | 1.5 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.4 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.3 M | Pfizer Inc | 2024-12-31 | 5.4 M | Nextech Invest Ag | 2024-12-31 | 5.3 M |
Oric Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 300.52 M | ||||
| Shares Outstanding | 71.03 M | ||||
| Shares Owned By Insiders | 9.43 % | ||||
| Shares Owned By Institutions | 90.57 % | ||||
| Number Of Shares Shorted | 12.04 M | ||||
| Price To Book | 2.28 X | ||||
| EBITDA | (142.9 M) | ||||
| Net Income | (127.85 M) | ||||
| Cash And Equivalents | 227.06 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 3.18 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 18.72 X | ||||
| Book Value Per Share | 3.42 X | ||||
| Cash Flow From Operations | (112.66 M) | ||||
| Short Ratio | 8.51 X | ||||
| Earnings Per Share | (1.83) X | ||||
| Target Price | 19.08 | ||||
| Number Of Employees | 115 | ||||
| Beta | 1.25 | ||||
| Market Capitalization | 553.3 M | ||||
| Total Asset | 274.14 M | ||||
| Retained Earnings | (562.77 M) | ||||
| Working Capital | 237.4 M | ||||
| Net Asset | 274.14 M |
About Oric Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oric Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oric Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oric Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out Oric Pharmaceuticals Piotroski F Score and Oric Pharmaceuticals Altman Z Score analysis. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.